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Abstract: The NF-B pathway is intimately linked to the survival of mammalian cells, and 
its  activation  by  Tax  has  consequently  been  considered  important  for  human  T-cell 
leukemia/lymphoma  virus  type 1 (HTLV-1)-infected cell resistance to death. Very little 
emphasis has been given to other mechanisms, although Tax regulates the expression and 
activity of several cellular genes. The finding that CREB protein is activated in HTLV-1 
infected cells underlines the possibility that other mechanisms of survival may be implicated 
in HTLV-1 infection. Indeed, CREB activation or overexpression plays a role in normal 
hematopoiesis, as well as in leukemia development, and CREB is considered as a survival 
factor in various cell systems. A better understanding of the different molecular mechanisms 
used by Tax to counteract cell death will also help in the development of new therapeutic 
strategies for HTLV-1 associated diseases.  
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1. Introduction  
The human T-cell leukemia/lymphoma virus type 1 (HTLV-1) is the etiological agent of a highly 
aggressive and fatal disease called adult T-cell leukemia/lymphoma (ATLL) [1,2]. The virus is also the 
causative  agent  of  tropical  spastic  paraparesis/HTLV-1-associated  myelopathy  (TSP/HAM),  a 
degenerative neurological illness [3], and other diseases, including polymyositis, uveitis, infectious 
dermatitis, immunodeficiency and arthropathy [4]. The onset of these pathologies is believed to be 
mainly a consequence of the expression of the viral protein Tax, which is also considered the major 
oncogenic protein of HTLV-1. Indeed, Tax has been shown to induce leukemia in transgenic mice [5], 
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and  to  immortalize  human  T  lymphocytes  when  expressed  in  either  a  herpes-  or  a  retroviral  
vector [6,7]. 
Tax is a 40 kDa phosphoprotein originally described as a nuclear protein [8,9], and subsequently 
found to shuttle from the nucleus to the cytoplasm [10–14]. In the nucleus, Tax is in part associated 
with speckled structures coincident with a subset of nuclear transcriptional hot spots [10], while in the 
cytoplasm Tax has been reported to be closely associated with Golgi compartments and localized in 
cell-cell contact regions [15]. The mechanisms regulating nucleus-cytoplasmic shuttling and targeting 
of  Tax  to  distinct  subcellular  regions  have  yet  to  be  determined,  but  it  is  conceivable  that  the 
pleiotropic nature of Tax activities might in part be determined by its subcellular localization.  
The  primary  and  most  studied  role  of  Tax  is  that  of  a  transcriptional  transactivator.  Tax  was 
identified as a trans-acting transcriptional activator for viral gene expression via the viral long terminal 
repeats (LTR) [16,17]. Successive studies have demonstrated that, by interacting with members of 
various transcription factor families that include cAMP-responsive element-binding protein/activating 
transcription factor (CREB/ATF), nuclear factor-B (NF-B), and serum responsive factor (SRF), Tax 
regulates  not  only  the  expression  of  HTLV-1,  but  also  that  of  several  cellular  genes  [17,18]. 
Furthermore, Tax has been found to modulate the function of numerous cellular proteins, including 
those involved in cell cycle regulation or belonging to signal transduction pathways and cytoskeleton, 
by directly interacting with them [19–23]. Tax expression has also been shown to reduce cellular 
genomic stability [24–27] and to interfere with most DNA repair mechanisms [28,29].  
Although ATLL generally presents prolonged incubation periods and ultimately only a minor subset 
(2–5%)  of  infected  individuals  develop  neoplasia,  once  the  disease  is  diagnosed  the  prognosis  is 
dismal. The poor outcome of patients with ATLL is mainly linked to intrinsic resistance of leukemic 
cells to conventional anticancer therapies that can be ascribed to decreased susceptibility to apoptosis 
shown  by  leukemic  cells.  Resistance  to  apoptosis  is  one  of  the  hallmarks  of  malignant  cell 
transformation [30] but also plays an important role in the pathogenesis of neurodegenerative and 
immunological disorders, all linked to HTLV-1 infection. 
Apoptosis can occur via two principal routes: the extrinsic (receptor-mediated) pathway and the 
intrinsic (mitochondrial) pathway. In the receptor-mediated pathway, interaction of the receptor with 
its ligand results in the oligomerization of the receptor’s intracellular death domains, and activation of 
the initiator caspase-8. The intrinsic apoptotic pathway requires pro-apoptotic proteins of the Bcl-2 
family  which  act  principally  at  the  mitochondrial  level.  Activation  of  these  proteins  by  apoptotic 
signals leads to changes in mitochondrial outer membrane permeability, release of cytochrome c, and 
activation of the initiator caspase 9 through the formation of the apoptosome. Both pathways induce 
activation of executioner caspases, and subsequent controlled destruction of cells. The link between the 
receptor-mediated signaling cascade and the mitochondria is provided by the Bcl-2 family member 
Bid. Bid is cleaved by caspase-8 and, in its truncated form (tBID), translocates to the mitochondria 
where it acts in concert with the proapoptotic Bcl-2 family members Bax and Bak to induce the release 
of cytochrome c and other mitochondrial pro-apoptotic factors into the cytosol [31,32]. 
While unbalanced activation of signal transduction pathways, inhibition of cell cycle checkpoint, 
and accumulation of genetic defects are generally associated with cell transformation and escape from 
apoptosis, the contribution of Tax to apoptosis has been a matter of discussion. Tax has been found to 
either induce [33–42] or inhibit [43–51] apoptotic cell death triggered by stimuli that activate either the Viruses 2011, 3                         
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extrinsic or the intrinsic pathway. However, genome expression profiling of Tax-positive cells showed 
that the viral protein down modulates a wide range of pro-apoptotic factors and stimulates expression 
of  factors  acting  as  anti-apoptotic  proteins  [52,53].  At  present,  it  is  generally  recognized  that  the  
anti-apoptotic activity of Tax overcomes its potential apoptotic role.  
Although the mechanism involved in the anti-apoptotic effect of Tax remains to be defined, it is 
believed that Tax prevents apoptosis by interfering with cell survival signaling cascades. So far, much 
attention has been given to the NF-B pathway, however, in the last years, at least two other cellular 
survival pathways have come to the forefront. 
In  this  review  we  will  briefly  discuss  new  findings  and  our  current  understanding  of  how  the 
NK-B,  PI3K/Akt,  Ras/Raf/ERK  pathways,  and  finally  CREB  activation,  are  engaged  by  Tax  to 
overcome cell death.  
2. NF-B Pathway 
NF-B family proteins are expressed in the cytoplasm of virtually all cell types, where their activity 
is controlled by a family of regulatory proteins called inhibitors of NF-B (IB). NF-B activation is 
tightly regulated by signals that degrade IB. In the canonical NF-B signaling pathway, IB proteins 
are phosphorylated by an activated IB kinase (IKK) complex. Phosphorylation leads to ubiquitination 
and degradation of IB, thus leaving the p50-RelA/p65 complex free to migrate to the nucleus. The 
IKK complex is composed of the catalytic subunits IKK and IKK and the regulatory subunit IKK, 
also known as NEMO (NF-B essential modulator). The IKK component is essential for signaling 
via the canonical NF-B pathway, while in the so-called non-canonical pathway IKK and IKK are 
dispensable and processing of NF-B2/p100 to p52/RelB dimers involves IKK homodimers. The 
canonical and non-canonical NF-B pathways regulate different B elements and, therefore, a distinct 
subset of NF-B target genes are controlled by the two pathways [54]. 
In  contrast  to  its  transient  mode  of  action  during  a  physiological  T-cell  response,  NF-B  is 
chronically activated in HTLV-1-transformed cell lines and freshly isolated ATLL cells [55], and this 
characteristic  has  been  ascribed  to  Tax  [56].  Tax  interferes  with  the  NF-B  pathway  via  direct 
Tax/IKK  subunit  interaction  which  leads  to  chronic  IKK  complex  activation,  continuous  IB 
degradation,  and  allows  the  translocation  of  NF-B  to  the  nucleus  [57–61]  (Figure  1).  Another 
mechanism  by  which  Tax  contributes  to  NF-B  activation  is  the  induction  of  the  non-canonical 
pathway, leading to processing of p100 and the formation of p52/RelB complex. This process, that 
usually operates in B cells and lymphoid stromal cells [62], is very active in HTLV-1-transformed 
cells [63]. In contrast to the cellular pathway, Tax stimulated processing of p100 does not need NIK 
(NF-B  inducing  kinase),  but  seems  to  require  IKK  [64,65]  (Figure  1).  Thus,  whereas  different 
physiological  inducers  of  NF-B activate  either the canonical or non-canonical pathway, Tax  can 
regulate both. Tax/NF-B pathway interaction is not confined to the cytoplasm. Indeed, it has been 
reported that Tax can activate transcription by directly binding NF-B subunits in the nucleus [66,67], 
and more recently, it has been shown that Tax sumoylation is critical for the recruitment f RelA to 
Tax nuclear bodies and transcriptional activation [68,69]. 
Activation  of  the  NF-B  pathway  is  considered  important  for  transformation,  proliferation  and 
survival of HTLV-1-infected cells. In accordance with this, treatment with specific NF-B pathway Viruses 2011, 3                         
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inhibitors  leads  to  suppression  of  growth  and  impaired tumorigenesis  in  mice  of  Tax-transformed 
fibroblasts [70], and induces apoptosis of HTLV-1-transformed T-cell lines and ATLL cells in vitro 
and in vivo [71–73]. 
Figure 1. Survival pathways controlled by Tax. A growing body of evidence suggests that 
the anti-apoptotic effect of Tax is mediated by the activation of distinct signaling cascades, 
including NF-B, PI3K/Akt and MEK/ERK1/2. Both canonical and non-canonical NF-B 
pathways are activated by Tax, and control the expression of numerous survival genes;  
the PI3K/Akt pathway, also activated by Tax, acts by inhibiting the pro-apoptotic protein 
Bad,  by  activating  the  NF-B  pathway  and  inducing  CREB  phosphorylation;  the 
Raf/MEK/ERK1/2 pathway is engaged by Tax through Ras activation. RasGTP can also 
induce PI3K activation; down modulation of PTEN expression by Tax leads to both Akt 
activation and increased levels of phosphorylated CREB in the nucleus. 
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3. PI3K/Akt Pathway 
The PI3K/Akt signaling pathway is a key regulator of numerous physiological cellular processes, 
including  proliferation  and  survival.  Unrestrained  activation  of  the  PI3K/Akt  pathway  has  been 
associated with malignant transformation and anti-apoptotic signaling. 
The phosphatidylinositol 3-kinase (PI3K) is a heterodimer, composed of a catalytic subunit (p110) 
and  a  regulatory  subunit  (p85),  which  is  activated  through  the  interaction  with  tyrosine  kinase 
receptors [74,75]. Akt, also known as protein kinase B (PKB), is a serine/threonine kinase and its 
activation is mediated by PI3K. Once activated, PI3K converts the plasma membrane lipid PI(4,5)P2 to Viruses 2011, 3                         
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PI(3,4,5)P3, and Akt is recruited by the latter to the plasma membrane. Translocation of Akt to the 
membrane  and  its  interaction  with  PI(3,4,5)P3  is  thought  to  provoke  the  exposure  of  two 
phosphorylation sites (Thr308 and Ser473); phosphorylation of Thr308 is mandatory for Akt activation 
while phosphorylation of Ser473 is required for full activation of the kinase [76]. Once activated Akt 
moves from the plasma membrane to both the cytoplasm and nucleus, where many of its substrates are 
located [76]. 
Akt regulates cellular survival by phosphorylation of substrates that directly or indirectly control the 
apoptotic machinery. For example, Akt induces the phosphorylation of Bad, a pro-apoptotic member 
of  the  Bcl-2  protein  family;  as  a  consequence,  Bad  dissociates  from  Bcl-XL  and  associates  with 
cytoplasmic 14-3-3 proteins with consequent loss of apoptotic activity [77]. Akt also appears to both 
negatively  regulate  factors  that  promote  the  expression  of  apoptotic  genes  and  positively  regulate 
factors  that  induce  survival  genes.  An  example  is  Akt’s  ability  to  activate  the  canonical  and  the  
non-canonical NF-B pathway by triggering IB phosphorylation and degradation, and by promoting 
the processing of p100 to p52, respectively [78,79]. Besides the NF-B pathway, Akt phosphorylates 
and  activates  CREB  mediated  transcription,  thus  controlling  expression  of  numerous  “survival”  
genes [80,81] (Figure 1).  
Negative regulation of the PI3K/Akt pathway is mainly accomplished by the tumor suppressor 
PTEN (phosphatase and tensin homologue deleted on chromosome 10), through its dual function as 
lipid and protein phosphatase, and by SHIP (src homology 2 domain containing inositol polyphosphate 
phosphatase-1). They regulate intracellular levels of activated Akt by dephosphorylating PI(3,4,5)P3; 
thus,  loss  of  PTEN  or  SHIP  expression  leads  to  permanent  activation  of  the  PI3K/Akt  signaling 
pathway [82,83]. 
Akt has been found to be activated in HTLV-1-transformed cells [84–86], and its activation has 
been  linked  to  apoptotic  resistance.  Peloponese  et  al.  [87]  suggested  that  Tax  promotes  Akt 
phosphorylation  by  directly  binding  the  p85  subunit  of  PI3K,  and  that,  in  the  absence  of  NF-B 
activation, Akt can promote survival through activation of AP-1 (activator protein-1). Ikezoe et al. [82] 
reported  that  downstream  of  Akt,  mTor  (mammalian  target  of  rapamycin)  was  activated  in  
HTLV-1-infected cells and that treatment with rapamycin (the inhibitor of mTor) surprisingly led to 
phosphorylation of Akt at Ser473. More recently, it has been suggested that Tax activates the PI3K 
signaling cascade by down regulating the PI(3,4,5)P3 phosphatases PTEN and SHIP-1 [88].  
Consistent  with  the  premise  that  Akt  is  one  of  the  survival  mechanism  of  Tax,  treatment  of  
Tax-positive cells with PI3K/Akt pathway inhibitors induces cell death [85,89]. 
4. CREB Activation 
CREB is a ubiquitously expressed, phosphorylation-dependent, transcriptional factor which acts by 
binding to cAMP response  element (CRE)  consensus  sequence, as a  homodimer or  by forming  a 
heterodimer with other members of the CREB family. Numerous stimuli and, by consequence, several 
kinases  including  Akt,  p90rsk,  protein  kinase  A  and  calcium/calmodulin-dependent  kinases  can 
phosphorylate CREB [90]. Although different residues may control CREB-dependent transcription, 
phosphorylation at Ser133 is essential for its activation by favoring CREB association with the histone 
acetyl-transferase  paralogs  CBP  (CREB-binding  protein)/p300,  and  subsequent  regulation  of  a Viruses 2011, 3                         
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multitude of genes. Indeed, consensus CRE sequences, or slight variants of this sequence, have been 
identified in hundreds of cellular genes. More recently, a phosphorylation-independent transcriptional 
activity of CREB, via its interaction with the transducers of regulated CREB activity (TORCs), has 
been  reported.  TORC  recruitment  does  not  seem  to  improve  CREB/DNA  binding,  but  rather  it 
enhances the interaction of CREB with a component of the transcriptional factor TFIID [91]. 
The vast number of functionally different genes regulated by CREB point out its critical relevance 
for many physiological cellular processes, including cell growth, and immune response [90,92–95], or 
aberrant  processes  as  escape  from  apoptosis  and  cell  transformation [96–101].  Indeed,  microarray 
analysis of cells treated with CRE decoy oligodeoxynucleotide revealed that many genes related to 
tumor growth are regulated by the CREB family of transcription factors [102,103].  
The role of CREB in HTLV-1-infected cells has thus far been considered only in terms of viral LTR 
activation. Transcription driven by cellular CREs, which lack the required GC-rich flanking sequences 
present in the viral CRE, have been considered less affected by Tax. However, the recent discovery 
that Tax might directly interact with the CREB co-activator TORC family of proteins, has uncovered 
the possibility that transcription of a significant number of cellular genes containing CRE sequences 
may be deregulated by Tax [104–107]. 
Our studies on the anti-apoptotic effects of Tax have indicated that CREB activation, rather than its  
NF-B transcriptional activity, is important in preventing cell death [47,49,108]. Indeed, we have shown 
that induction of a specific block in CREB transactivation using dominant negative CREB mutants 
increased apoptosis, whilst triggering CREB phosphorylation with forskolin reduced apoptosis [108].  
We have also observed that HeLa cells expressing Tax exhibit higher levels of Ser133-phosphorylated 
CREB  compared  to  control  cells,  suggesting  that  Tax  might  influence  the  phosphorylation  state  
of CREB [49]. 
In agreement with our results, Kim et al. [109] observed higher levels of intracellular p-CREB in a 
panel of HTLV-1-infected versus uninfected T cell lines. They also demonstrated that Tax expression 
was directly involved in the enhanced CREB phosphorylation. These findings suggest that the virus 
has evolved a mechanism to elevate pCREB levels in the HTLV-1-infected cells, likely as a way to 
promote  strong  Tax-mediated  transactivation  of  CREB-responsive  genes.  It  also  seems  that  in  
HTLV-1-infected cells [109] or in HeLa cells transfected with Tax [108], the intracellular CREB is 
maximally phosphorylated, when compared to forskolin treatment. 
Interestingly, Wu et al. [23], using a proteomic approach, reported that Tax can bind to several 
small  GTPase-cytoskeleton  proteins,  including  RhoA,  Rac,  Cdc42,  and  the  RasGTPase  activating 
protein GAP
1m. In addition, using HeLa cells, we showed that while Tax physically interacts with 
GAP
1m, its CREB-deficient mutant M47 (unable to protect cells from apoptosis [108]), binds to it with 
lower affinity [110]. Based on these findings, we proposed a model of Tax-mediated RasGTP (active 
form) accumulation, Raf/MEK/ERK pathway activation and CREB phosphorylation. In line with this, 
it  has  been  shown  that  the  inhibition  of  protein  geranylgeranylation  or  farnesylation  has  
anti-proliferative and apoptotic effects in HTLV-1-infected cells [111].  
CREB is also a target of Akt and, as mentioned above, Tax can activate the PI3K/Akt pathway both 
by interacting with PI3K or down regulating the expression of PTEN [88]; it is also interesting to point 
out that PI3K is a downstream effector of Ras. In addition, more recently, Gu et al. [112] reported that 
PTEN  phosphatase  activity  is  required  for  CREB  dephosphorylation  at  Ser133  in  the  nucleus, Viruses 2011, 3                         
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suggesting  that  PTEN  deficiency  (or  down  regulation)  can  increase  the  levels  of  CREB 
phosphorylation independently of PI3K/Akt or Raf/MEK/ERK activity (Figure 1). 
5. Conclusions  
The Tax protein is considered the main oncogenic product of HTLV-1; most likely one of the 
mechanisms involved in Tax-mediated transformation is its capability to alter the delicate balance 
between  cell  death  and  survival.  Much  evidence  has  led  to  consider  the  activation  of  the  NF-B 
pathway as the principal survival mechanism of Tax, and has restricted Tax-induced CREB activity to 
viral gene expression. However, the information gathered so far suggests that Tax, besides activation 
of  the  NF-B  pathway,  can  exert  its  anti-apoptotic  activity  by  affecting  CREB  phosphorylation 
through activation of the PI3K/Akt and, possibly, of the Raf/MEK/ERK pathways, both of which list 
CREB as a downstream effector.  
Thus, in order to be more effective, therapeutic approaches to ATLL must take into account the 
many interconnections between the survival pathways engaged by Tax, and develop strategies that 
simultaneously block different targets.  
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